Replies to post #511256 on NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

If this were a monopsony that would make sense. But to the extent there are multiple potential buyers or partners, the company is well past the stage of vultures circling above their heads. Whatever form the deal takes has already been agreed, perhaps even years ago.

[skitahoe]

I agree with you completely. Frankly I believe we're premature in speaking of partnerships or buyouts until our share price is roughly ten times or more than what it is today for a partnership, or nearly twenty times what it is today for a buyout. I simply don't think that LP would consider an offer that wasn't nearly double the share price and it will take that sort of share prices to meet her demands.

Like you, I believe she's positioned the company to go it alone as long as they have to, and they could be so well positioned that they choose not to take either a partnership or buyout offer. I don't believe it will ever be something they must do, it will always be a choice.

Age of the officers shouldn't be the determining factor. Any of them could step down to other roles, or retire completely and be very well to do with the success the company's about to have. With success it will be no problem at all attracting top flite personnel if one or more key positions became open. As soon as the share price warrants a move to a major exchange LP should fill key positions rather than filling more than one herself, it would probably be required to move to a major exchange, but regardless she should do it as soon as she has the funding to support it.

I prefer a BP partnership to a buyout, but wouldn't object at all if the company chooses to go it alone, though clearly dilutive funding will be needed to support an aggressive clinical trials campaign to expand the label on DCVax-L and advance Direct toward approval in multiple cancers. Can you imagine the market cap NWBO would have if it remained independent and both DCVax-L and Direct were approved in multiple solid cancers. I frankly also believe that FlaskWorks, as a separate unit, could be huge in licensing to others for making a variety of personalized products which don't in any way compete with the DCVax's.

Gary

[Doc logic]

Horseb4CarT,

When you have one shot to get it right, have never taken a product all the way to approval and have the potential to change the way all or almost all solid tumor cancers are treated, time becomes a commodity you need lots of to keep that potential in house. This means staying the course no matter how painful it seems to be to buy into by those focused on the limited perspective of a single indication instead of the platform. Linda has saved the true value of this tech for long term shareholders who stayed the course and will grant much higher priced derisked shares to those who have demonstrated good faith interest in partnering. Looking forward to that news for patients and as a reward for those who looked at the big picture and stood by NWBO. Many are here in honor of those that brought them here looking for a cure for loved ones. This motive has helped NWBO bring a history making breakthrough treatment to many current and future cancer patients in spite of multiple obvious attempts to get those investors to capitulate to fear. Longs standing firm reminds me of the portion of scripture in 1John 4:18 that states “..perfect love drives out fear...”. Motivations matter. Best wishes,